retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide Phase 2: Type 2

A multicenter, randomized, double-blind, multiple dose-escalation study showed that after 4 weeks of treatment of PEX-168 with different doses, the weight decreased by -0.8-1.8kg

2, 13 Dec

What happens if someone is undernourished after years of eating a poor diet on these appetite-suppressing drugs and then gets to the point where they can no longer obtain them

While SURPASS-4 was not powered to evaluate differences in MACE-4 incidence between tirzepatide treatment groups and glargine, it was designed to fulfill the MACE-4 non-inferiority analysis requested by regulatory authorities to evaluate the cardiovascular safety of new glucose lowering medications

They used a mouse model of diet-induced obesity and combined metabolomic analyses in BAT and other tissues with stable-isotope tracer studies to answer this question

Aleksandr Shapsis, MD Key Takeaways: As the Tristate leader in non-surgical weight loss, EndoSlim Clinic NY is at the forefront of metabolic medicine